Sermo, Bloomberg partner on service for healthcare investors

Share this article:
Sermo has teamed up with Bloomberg to develop a groundbreaking forum that gives healthcare investors instant access to medical information and the opinions of its community of physicians—a venture that Sermo CEO Daniel Palestrant, MD, believes “has the potential to reward with greater investment those products and services that are most effective, rather than those that are well-promoted.”

The Healthcare Exchange, demonstrated for the first time to a select audience of industry leaders last night in San Francisco, gives users direct access to the observations and insights of Sermo's 90,000-strong physician community through the Bloomberg Professional Service. With one click, 280,000-plus analysts and investors can gain instant access to what Palestrant described as “the front-lines of medicine,” giving users “actionable intelligence about therapies and devices” on which to base investing decisions—and effectively offering early intelligence of market-changing events in healthcare.

Investors and analysts will be able to pose questions to physicians to gauge opinion and reactions to potentially market-changing information, such as company statements about the efficacy of therapies or media stories about adverse events.

Palestrant told the invitation-only audience that the Healthcare Exchange will “tear down” barriers to information. “For physicians, this provides a voice beyond the bound of their community,” he said. “For investors, it is a disruptive technology that leads to more transparent information and better investment decisions.”

The new service will become a feature of the Bloomberg function BDRUG, which provides daily-updated information on every drug marketed in the US, from clinical trials results to prescription data, and will be available as part of the Bloomberg Professional service.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...